BARNES-JEWISH HOSPITAL
WASHINGTON UNIVERSITY SCHOOL OF MEDICINE
About Us
News & Events
Maps & Locations
Contact Us
Google Search
PATIENT AND VISITOR INFORMATION
TREATMENT PROGRAMS
PREVENTION AND SCREENING
RESEARCH
HOW TO HELP
FOR HEALTH PROFESSIONALS
Go back to:
Home
Treatment Programs
Types of Cancer
Clinical Trial Search Results
Share
Esophageal Cancer
NCI Information
Clinical Trials
Support Groups
Effects of Treatment
Podcast
Treatment Team
NEW SEARCH
RETURN TO SEARCH RESULTS
Number:
201102254
Principal Investigator:
Edmundowicz, Steven
Title:
Endoscopic Resection or Ablation for Patients with Dysplasia or Intramucosal Cancer Requiring Treatment of Barrett’s Esophagus: the ERADICATE trial A Multi-Center Randomized Controlled Trial
Phase:
II
Disease Site:
Esophagus
Participating Site(s):
Main Campus
Map and Directions
Contact:
800-600-3606 or
info@ccadmin.wustl.edu
Description:
This is a multi-center prospective, RCT conducted at 4 centers. 82 patients with HGD and/or EC who meet the study criteria will be enrolled, undergo a baseline diagnostic EMR and then be randomized in a 1:1 ratio to undergo treatment by either stepwise endoscopic mucosal resection (S-EMR) or radiofrequency ablation (RFA). The initial staging EMR will not extend more than 50% of the esophageal circumference or more than 2 cm in longitudinal extent. Patients in the S-EMR group will undergo step-wise eradication of the BE segment using the Duette multi-band mucosectomy kit (Cook Medical, FDA approved) whereas those in the RFA group will undergo BE ablation using the endoscopically-guided HALO radiofrequency ablation system (Barrx Medical, FDA approved).
More Information:
(Links will take you off this web site)
Internal Protocol Documents (requires Siteman administrative database password)